WO2001035899A3 - Inhibitors of helicobacter pylori induced gastrointestinal diseases - Google Patents

Inhibitors of helicobacter pylori induced gastrointestinal diseases Download PDF

Info

Publication number
WO2001035899A3
WO2001035899A3 PCT/EP2000/011444 EP0011444W WO0135899A3 WO 2001035899 A3 WO2001035899 A3 WO 2001035899A3 EP 0011444 W EP0011444 W EP 0011444W WO 0135899 A3 WO0135899 A3 WO 0135899A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
helicobacter pylori
gastrointestinal diseases
induced gastrointestinal
pylori induced
Prior art date
Application number
PCT/EP2000/011444
Other languages
French (fr)
Other versions
WO2001035899A2 (en
WO2001035899A9 (en
Inventor
Christian Wallasch
Dorian Bevec
Original Assignee
Axxima Pharmaceuticals Ag
Christian Wallasch
Dorian Bevec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axxima Pharmaceuticals Ag, Christian Wallasch, Dorian Bevec filed Critical Axxima Pharmaceuticals Ag
Priority to EP00990605A priority Critical patent/EP1229925A2/en
Priority to JP2001537695A priority patent/JP2003513995A/en
Priority to AU30037/01A priority patent/AU3003701A/en
Publication of WO2001035899A2 publication Critical patent/WO2001035899A2/en
Publication of WO2001035899A3 publication Critical patent/WO2001035899A3/en
Publication of WO2001035899A9 publication Critical patent/WO2001035899A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention refers to a method for the manufacture of a medicament for treating or preventing Helicobacter mediated diseases in a mammal and a method for treating or preventing Helicobacter mediated diseases.
PCT/EP2000/011444 1999-11-19 2000-11-17 Inhibitors of helicobacter pylori induced gastrointestinal diseases WO2001035899A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00990605A EP1229925A2 (en) 1999-11-19 2000-11-17 Inhibitors of helicobacter pylori induced gastrointestinal diseases
JP2001537695A JP2003513995A (en) 1999-11-19 2000-11-17 Inhibitors of gastrointestinal diseases induced by Helicobacter pylori
AU30037/01A AU3003701A (en) 1999-11-19 2000-11-17 Inhibitors of helicobacter pylori induced gastrointestinal diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP99123042.6 1999-11-19
EP99123042 1999-11-19
US44801399A 1999-11-23 1999-11-23
US09/448,013 1999-11-23

Publications (3)

Publication Number Publication Date
WO2001035899A2 WO2001035899A2 (en) 2001-05-25
WO2001035899A3 true WO2001035899A3 (en) 2001-12-13
WO2001035899A9 WO2001035899A9 (en) 2002-09-19

Family

ID=26153172

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/011444 WO2001035899A2 (en) 1999-11-19 2000-11-17 Inhibitors of helicobacter pylori induced gastrointestinal diseases

Country Status (4)

Country Link
EP (1) EP1229925A2 (en)
JP (1) JP2003513995A (en)
AU (1) AU3003701A (en)
WO (1) WO2001035899A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1174129A1 (en) * 2000-07-17 2002-01-23 Zenner, Hans Peter, Prof. Dr. med. Use of a matrix-metalloprotease inhibitor for the treatment of cancer
US20050176633A1 (en) * 2002-03-08 2005-08-11 Axel Ullrich Use of egfr transactivation inhibitors in human cancer
WO2009108390A2 (en) * 2008-02-29 2009-09-03 Acorda Therapeutics, Inc. Method for achieving desired glial growth factor 2 plasma levels
AU2014352875B2 (en) 2013-11-22 2019-10-24 CL BioSciences LLC Gastrin antagonists (eg YF476, netazepide) for treatment and prevention of osteoporosis
WO2018151285A1 (en) * 2017-02-20 2018-08-23 学校法人順天堂 Prophylactic or therapeutic drug for itching skin diseases

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002039A1 (en) * 1995-07-04 1997-01-23 Pharmacia & Upjohn S.P.A. Antibacterial synergistic composition comprising rifabutin
JPH09183764A (en) * 1995-12-28 1997-07-15 Roussel Morishita Kk N-benzoylproline ester derivative
WO1998048836A1 (en) * 1997-04-30 1998-11-05 Merieux Oravax Anti-helicobacter vaccine composition comprising a th1 adjuvant
JPH11124368A (en) * 1997-10-22 1999-05-11 Takeda Chem Ind Ltd Bioactive substance, its production and agent
WO1999032463A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS
JPH11189529A (en) * 1997-12-25 1999-07-13 Toray Ind Inc Anti-helicobacter pylori agent
WO1999055335A1 (en) * 1998-04-30 1999-11-04 Basf Aktiengesellschaft Substituted tricyclic pyrazole derivatives with protein kinase activity
WO1999065513A2 (en) * 1998-06-18 1999-12-23 Chowers Michal Y Pharmaceutical compositions for the treatment of helicobacter pylori-associated disorders

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002039A1 (en) * 1995-07-04 1997-01-23 Pharmacia & Upjohn S.P.A. Antibacterial synergistic composition comprising rifabutin
JPH09183764A (en) * 1995-12-28 1997-07-15 Roussel Morishita Kk N-benzoylproline ester derivative
WO1998048836A1 (en) * 1997-04-30 1998-11-05 Merieux Oravax Anti-helicobacter vaccine composition comprising a th1 adjuvant
JPH11124368A (en) * 1997-10-22 1999-05-11 Takeda Chem Ind Ltd Bioactive substance, its production and agent
WO1999032463A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS
JPH11189529A (en) * 1997-12-25 1999-07-13 Toray Ind Inc Anti-helicobacter pylori agent
WO1999055335A1 (en) * 1998-04-30 1999-11-04 Basf Aktiengesellschaft Substituted tricyclic pyrazole derivatives with protein kinase activity
WO1999065513A2 (en) * 1998-06-18 1999-12-23 Chowers Michal Y Pharmaceutical compositions for the treatment of helicobacter pylori-associated disorders

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
BEIL W ET AL: "The Helicobacter pylori fatty acid cis-9,10-methyleneoctadecanoic acid stimulates protein kinase C and increases DNA synthesis of gastric HM02 cells.", BRITISH JOURNAL OF CANCER, vol. 77, no. 11, June 1998 (1998-06-01), pages 1852 - 1856, XP001009925, ISSN: 0007-0920 *
BHAGWAT SS ET AL: "Gene-regulating protein kinases as important anti-inflammatory targets", DDT, vol. 4, no. 10, October 1999 (1999-10-01), pages 472 - 479, XP002170705 *
DATABASE WPI Section Ch Week 199738, Derwent World Patents Index; Class B03, AN 1997-410809, XP002170711 *
DATABASE WPI Section Ch Week 199929, Derwent World Patents Index; Class B03, AN 1999-341624, XP002170713 *
DATABASE WPI Section Ch Week 199938, Derwent World Patents Index; Class B05, AN 1999-452896, XP002170712 *
GOEKJIAN PETER G ET AL: "Protein kinase C in the treatment of disease: Signal transduction pathways, inhibitors, and agents in development.", CURRENT MEDICINAL CHEMISTRY, vol. 6, no. 9, September 1999 (1999-09-01), pages 877 - 903, XP001009989, ISSN: 0929-8673 *
GOLDENBERG M M: "TRASTUZUMAB, A RECOMBINANT DNA-DERIVED HUMANIZED MONOCLONAL ANTIBODY, A NOVEL AGENT FOR THE TREATMENT OF METASTATIC BREAST CANCER", CLINICAL THERAPEUTICS,EXCERPTA MEDICA, PRINCETON, NJ,US, vol. 21, no. 2, 1999, pages 309 - 318, XP000918210, ISSN: 0149-2918 *
HUGHES J ET AL: "DEVELOPMENT OF A CLASS OF SELECTIVE CHOLECYSTOKININ TYPE B RECEPTOR ANTAGONISTS HAVING POTENT ANXIOLYTIC ACTIVITY", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 87, no. 17, 1990, 1990, pages 6728 - 6732, XP002170707, ISSN: 0027-8424 *
KEATES S ET AL: "Differential activation of mitogen-activated protein kinases in AGS gastric epithelial cells by cag+ and cag- Helicobacter pylori.", JOURNAL OF IMMUNOLOGY, (1999 NOV 15) 163 (10) 5552-9., XP002170708 *
MITAMURA T ET AL: "DIPHTHERIA TOXIN BINDS TO THE EPIDERMAL GROWTH FACTOR (EGF)-LIKE DOMAIN OF HUMAN HEPARIN-BINDING EGF-LIKE GROWTH FACTOR/DIPHTHERIA TOXIN RECEPTOR AND INHIBITS SPECIFICALLY ITS MITOGENIC ACTIVITY", JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 270, no. 3, 20 January 1995 (1995-01-20), pages 1015 - 1019, XP002912324, ISSN: 0021-9258 *
NAUMANN MICHAEL ET AL: "Activation of activator protein 1 and stress response kinases in epithelial cells colonized by Helicobacter pylori encoding the cag pathogenicity island.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 44, 29 October 1999 (1999-10-29), pages 31655 - 31662, XP002170706, ISSN: 0021-9258 *
PRENZEL NORBERT ET AL: "EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF.", NATURE (LONDON), vol. 402, no. 6764, 23 December 1999 (1999-12-23), pages 884 - 888, XP002136695, ISSN: 0028-0836 *
REVEL LAURA ET AL: "Update on nonpeptide CCK-B receptor antagonists.", DRUGS OF THE FUTURE, vol. 23, no. 7, July 1998 (1998-07-01), pages 751 - 766, XP001009876, ISSN: 0377-8282 *
TARNAWSKI AS: "The role of epidermal growth factor (EGF) and its receptor in mucosal protection, adaptation to injury, and ulcer healing: Involvement of EGF-R signal transduction pathways", JOURNAL OF CLINICAL GASTROENTEROLOGY, vol. 27, no. suppl 1, 1998, pages S12 - S20, XP001010005 *
TRAXLER PETER ET AL: "Recent advances in protein tyrosine kinase inhibitors.", DRUGS OF THE FUTURE, vol. 20, no. 12, 1995, pages 1261 - 1274, XP001009877, ISSN: 0377-8282 *
WOJTOWICZ-PRAGA SLAWOMIR M ET AL: "Matrix metalloproteinase inhibitors.", INVESTIGATIONAL NEW DRUGS, vol. 15, no. 1, 1997, pages 61 - 75, XP001009881, ISSN: 0167-6997 *

Also Published As

Publication number Publication date
WO2001035899A2 (en) 2001-05-25
JP2003513995A (en) 2003-04-15
AU3003701A (en) 2001-05-30
WO2001035899A9 (en) 2002-09-19
EP1229925A2 (en) 2002-08-14

Similar Documents

Publication Publication Date Title
AU2001269742A1 (en) Method of treating gastrointestinal diseases associated with species of genus clostridium
AU5714601A (en) Methods for prevention and treatment of gastrointestinal disorders
AU2002234021A1 (en) Method and device for the treatment of vulnerable tissue site
AU2002211304A1 (en) Systems and methods for assessing vascular effects of a treatment
AU2002218001A1 (en) Method and apparatus for the treatment of gastric ulcers
PL364995A1 (en) Method for the treatment or prevention of flavivirus
AU2003235613A1 (en) Crude drug compositions for treating or preventing arthritic diseases and the preparation process
WO1999005096A3 (en) Urokinase inhibitors
NO985484D0 (en) Method and preparation for the treatment and prevention of hyperuricemia
ZA200004406B (en) Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal.
AU2002237667A1 (en) Methods for the treatment and prevention of urinary stone disease
EP1099442A3 (en) Methods of administering apo B-secretion/MTP inhibitors
WO2002068071A8 (en) Multiple-stage game of chance and method of and system for playing the game
AU2002220266A1 (en) Methods for the identification and the treatment of cardiovascular disease
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
AU2002235692A1 (en) Methods and compositions for preventing and treating neutrophil-mediated diseases
WO2001035899A3 (en) Inhibitors of helicobacter pylori induced gastrointestinal diseases
AU2388601A (en) A method and system for facilitating the playing of a game
AU2002349268A1 (en) Medicine for preventing and treating bromidrosis
AU2002235153A1 (en) Medical guidewire and method for making
IS6707A (en) Preparation for the prevention and treatment of cancer
EP1280546A4 (en) Method and composition for the treatment of angiogenesis
AU2001238179A1 (en) Method and compositions for treating hepatocellular cancer
NO20026148L (en) Medications for the prevention and treatment of neurodegenerative diseases
AU2001238288A1 (en) Method and compositions for treating fibrotic diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000990605

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10130142

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2001 537695

Country of ref document: JP

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2000990605

Country of ref document: EP

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/7-3/7, 5/7 AND 6/7, DRAWINGS, REPLACED BY NEW PAGES 1/7-3/7, 5/7 AND 6/7; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000990605

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)